A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
Fiche publication
Date publication
mars 2017
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr BOUCHE Olivier
Tous les auteurs :
Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T, Raoul W
Lien Pubmed
Résumé
Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer. Some studies have previously shown that IL-17A and IL-17F polymorphisms, respectively rs2275913 and rs763780, are associated with gastric or colorectal cancer risk. Here we aimed at studying the influence of IL-17A-related individual factors on overall survival and progression-free survival in patients with metastatic colorectal cancer treated with a bevacizumab-based chemotherapy.
Mots clés
Bevacizumab, IL-17 polymorphisms, Metastatic colorectal cancer, Survival analysis: score, Th17-related cytokines, Vascular endothelial growth factor
Référence
BMC Cancer. 2017 Mar;17(1):220